
Alterome Therapeutics Reports Preliminary Phase 1 Results for ALTA3263, Showing Antitumor Activity Across KRAS Mutations in Colorectal and Pancreatic Cancers
Alterome Therapeutics, Inc., a clinical-stage precision oncology company focused on discovering and developing alteration-specific therapies against oncogenic drivers, has announced preliminary clinical findings from the Phase 1 dose-escalation portion of its ongoing Phase 1/1b trial evaluating ALTA3263 in adults with KRAS-mutant advanced solid tumors. The investigational oral therapy is designed as a KRAS-selective, pan-mutant, active/inactive (ON/OFF) inhibitor intended to target a broad range of KRAS mutations.
The preliminary findings were presented in a late-breaking oral session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), held in Barcelona, Spain. The results provide early evidence of antitumor activity with ALTA3263 both in combination with cetuximab in patients with advanced metastatic colorectal cancer (CRC) and as a monotherapy in patients with advanced metastatic pancreatic ductal adenocarcinoma (PDAC).
The clinical findings are based on data available through September 18, 2026. Pharmacokinetic analyses showed increasing, approximately dose-proportional drug exposure across doses ranging from 100 mg to 400 mg administered twice daily. At the 400 mg twice-daily dose, exposure exceeded preclinical steady-state benchmarks. This finding provides important information for continued dose evaluation and the development of potential combination treatment strategies.
Antitumor activity was observed across several KRAS mutations, including G12D, G12V, G12A, G13D and Q61H. Most treatment-related adverse events (TRAEs) were Grade 1 or Grade 2, although some patients experienced higher-grade events and dose reductions. The maximum tolerated dose had not been reached as of the data cutoff.
ALTA3263 was developed to inhibit a broad range of mutant KRAS variants while sparing wild-type HRAS and NRAS. This selectivity profile is intended to support its potential use alongside anti-epidermal growth factor receptor (EGFR) inhibitors, established standard-of-care treatments and other targeted therapies. By addressing multiple KRAS mutations rather than focusing on a single variant, the investigational therapy could potentially expand targeted treatment opportunities for patients with cancers driven by KRAS alterations.
“Preliminary data from the Phase 1 dose-escalation portion of ALTA3263’s trial in CRC and PDAC patients demonstrate its potential to improve upon currently available therapies and address a broad range of KRAS mutations, potentially expanding treatment options for patients who remain in need of more effective and tolerable therapies,” said Leo Faoro, M.D., MBA, Chief Medical Officer of Alterome Therapeutics.
Faoro added that the findings support the company’s continued development of ALTA3263 in colorectal and pancreatic cancers. He also highlighted the rationale for evaluating the drug in earlier lines of treatment in combination with standard-of-care regimens and targeted therapies.
ALTA3263 and the need for broader KRAS-targeted treatment in colorectal cancer
KRAS mutations are common in colorectal cancer and represent an important driver of tumor development and progression. Approximately 50% of colorectal cancers harbor KRAS mutations, making this disease an important area of unmet medical need for targeted therapies.
The most frequently observed KRAS alterations in CRC include G12D, which accounts for approximately 33% of mutations, followed by G12V at 22%, G13D at 14% and G12C at 7%. Despite advances in targeted oncology, currently approved KRAS-targeted treatment options remain limited to patients with KRAS G12C mutations. Consequently, patients with other KRAS variants continue to have limited access to mutation-specific treatment approaches.
ALTA3263 is designed to address this gap through its broader mutant KRAS inhibition profile. Rather than concentrating on a single mutation, the investigational drug is intended to inhibit several KRAS-mutant forms while preserving wild-type HRAS and NRAS. This approach could potentially support treatment strategies for a wider range of patients whose tumors are driven by different KRAS alterations.
The combination of KRAS inhibitors with anti-EGFR therapies is another important area of investigation in colorectal cancer. EGFR-mediated feedback signaling can limit the effectiveness of KRAS inhibition, potentially contributing to resistance or reduced treatment activity. Combining a KRAS inhibitor with an anti-EGFR agent may help address this signaling response and improve antitumor activity.
Alterome is therefore evaluating ALTA3263 alongside cetuximab, an anti-EGFR antibody, to investigate whether the combination can provide meaningful clinical activity in patients with KRAS-mutant CRC. The preliminary findings from the Phase 1 dose-escalation study offer initial support for this strategy.
Phase 1 study enrollment and patient characteristics
As of September 18, 2026, a total of 120 patients had received ALTA3263 in the ongoing Phase 1/1b clinical trial. Of these, 80 patients received ALTA3263 as a monotherapy, while 40 patients were treated with the investigational drug in combination with cetuximab.
Participants had received a median of two prior lines of systemic therapy in the advanced disease setting, with the number of previous treatment lines ranging from zero to nine. The study included patients with several tumor types, reflecting the trial’s focus on advanced solid tumors carrying KRAS mutations.
The distribution of tumor types among enrolled patients was:
- Pancreatic ductal adenocarcinoma: 46%
- Colorectal cancer: 42%
- Non-small cell lung cancer: 10%
- Other tumor types: 3%
The KRAS mutation profile also demonstrated the broad range of alterations represented in the study. KRAS G12V accounted for 40% of patients, followed by G12D at 38%, G12A at 8%, G13D at 7%, Q61H at 4% and other mutations at 3%.
The maximum tolerated dose had not been reached at the time of the analysis. The ongoing dose-escalation process is intended to provide additional information about the appropriate dosing range, tolerability and potential activity of ALTA3263 across different treatment settings.
Combination treatment demonstrates preliminary activity in KRAS-mutant colorectal cancer
The Phase 1 dose-escalation results showed preliminary antitumor activity when ALTA3263 was administered with cetuximab to patients with KRAS-mutant advanced colorectal cancer.
The response analysis included 16 evaluable patients who received ALTA3263 at doses of 200 mg or 300 mg twice daily in combination with cetuximab. These patients had initiated treatment at least 14 weeks before the September 18, 2026 data cutoff and had undergone a post-baseline tumor scan.
Among the 16 patients evaluated, five achieved partial responses. Four of these responses were confirmed, while one remained unconfirmed at the time of the analysis. This resulted in an objective response rate (ORR) of 31%, representing five responses among 16 patients.
Disease control was observed in 15 of the 16 patients, corresponding to a disease control rate (DCR) of 94%. Tumor regression was also reported in 15 of 16 patients with post-baseline target-lesion assessments, representing 94% of the evaluated group.
Responses were observed across multiple KRAS mutations, supporting the intended broad mutant-allele coverage of ALTA3263. This is an important aspect of the program because colorectal cancer patients with KRAS alterations other than G12C have limited mutation-specific targeted treatment options.
Although the patient population was relatively small and the results remain preliminary, the observed responses and disease control provide an early indication of the potential activity of ALTA3263 combined with cetuximab. Further clinical evaluation will be needed to establish the durability and consistency of these findings in larger patient groups.
Safety and tolerability of ALTA3263 plus cetuximab
The safety analysis of the combination regimen included all 40 patients who received ALTA3263 with cetuximab. Most treatment-related adverse events were mild to moderate, with 62% of patients experiencing Grade 1 or Grade 2 TRAEs.
No patients discontinued treatment because of treatment-related adverse events. However, Grade 3 or higher TRAEs occurred in 33% of patients, and six patients, representing 15% of the combination-treatment group, required ALTA3263 dose reductions due to TRAEs.
The most frequently reported treatment-related adverse events included:
- Diarrhea: 83%
- Dermatitis acneiform: 68%
- Nausea: 63%
- Vomiting: 45%
Grade 3 dermatitis acneiform was reported in 8% of patients. These findings highlight the importance of continued safety monitoring as the combination regimen moves through further clinical evaluation.
The absence of treatment discontinuations due to TRAEs is a relevant observation from this preliminary dataset. Nevertheless, the incidence of Grade 3 or higher adverse events and the need for dose reductions demonstrate that tolerability remains an important consideration in determining the appropriate dose and treatment schedule.
Alterome plans to continue investigating ALTA3263 in combination with cetuximab, with the aim of further understanding its safety profile and potential role in treating KRAS-mutant colorectal cancer.
David S. Hong, M.D., Deputy Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, commented on the early combination findings.
“The activity observed with ALTA3263 plus cetuximab in KRAS-mutant colorectal cancer is particularly encouraging, with responses across multiple KRAS mutations in a setting where this level of activity has historically been difficult to achieve,” Hong said.
He added that the early results suggest ALTA3263 combined with cetuximab could offer a potential new treatment approach for patients with KRAS-mutant colorectal cancer, where available targeted treatment options remain limited.
ALTA3263 monotherapy demonstrates early activity in pancreatic cancer
In addition to its evaluation in colorectal cancer, Alterome is investigating ALTA3263 as a single-agent treatment for pancreatic ductal adenocarcinoma. PDAC is among the most aggressive and difficult-to-treat cancers, and KRAS mutations are present in more than 90% of cases.
Despite progress in the development of KRAS-directed therapies, patients with pancreatic cancer continue to face substantial treatment challenges. There remains a need for targeted therapies that can provide antitumor activity while maintaining a tolerability profile suitable for combination treatment approaches.
Alterome believes the preliminary monotherapy findings provide a basis for continued investigation of ALTA3263 in PDAC, including potential combinations with standard-of-care regimens and other targeted therapies. Evaluating the drug earlier in the treatment course may also help determine whether it can contribute to broader treatment strategies for this patient population.
During the Phase 1 dose-escalation portion of the trial, ALTA3263 monotherapy demonstrated antitumor activity in patients with PDAC who received doses of 400 mg or 600 mg twice daily.
The preliminary response analysis included 13 evaluable patients who had initiated treatment at least 14 weeks before the September 18, 2026 data cutoff and had undergone a post-baseline scan.
Three patients achieved confirmed partial responses, resulting in a confirmed objective response rate of 23%, or three responses among 13 patients. Disease control was observed in 10 of the 13 patients, corresponding to a DCR of 77%.
Tumor regression was observed in 10 of 12 patients who had post-baseline target-lesion assessments, representing 83% of the evaluable group for this measure.
These findings indicate preliminary single-agent activity in a cancer type characterized by a high prevalence of KRAS mutations and limited treatment options. However, the results are based on a small number of response-evaluable patients and require confirmation through additional clinical investigation.
The company plans to continue evaluating ALTA3263 in pancreatic cancer, including its potential use in combination regimens. The objective is to determine whether the investigational therapy can be integrated into treatment approaches that may address the needs of patients with advanced PDAC.
Monotherapy safety findings across tumor types
The safety profile of ALTA3263 monotherapy was assessed across the 80 patients treated with the investigational drug alone, including patients with different KRAS-mutant tumor types.
Grade 3 or higher treatment-related adverse events were reported in 15% of patients. The most frequently reported TRAEs were diarrhea, vomiting, nausea and fatigue. These events occurred predominantly at Grade 1 or Grade 2 severity.
The most common treatment-related adverse events were:
- Diarrhea: 51%
- Vomiting: 46%
- Nausea: 45%
- Fatigue: 31%
Dermatitis acneiform was reported in 11% of patients, and all reported cases were Grade 1 or Grade 2.
One dose-limiting toxicity was observed during monotherapy dose escalation. The event involved Grade 3 diarrhea at the 400 mg twice-daily dose. This finding will be considered alongside the broader safety and pharmacokinetic data as the company continues evaluating dose levels and treatment schedules.
The overall preliminary safety findings provide information about the tolerability of ALTA3263 as a single agent. Most reported adverse events were low grade, although the occurrence of Grade 3 or higher events and the dose-limiting toxicity underscore the need for continued monitoring as additional patients are treated.
Continued clinical development and next steps
The ongoing Phase 1/1b study of ALTA3263 is an open-label, dose-escalation and multiple-cohort clinical trial evaluating adults with advanced solid tumor malignancies carrying KRAS mutations. The study is registered under ClinicalTrials.gov identifier NCT06835569.
The trial is designed to assess the investigational therapy across different dose levels and treatment cohorts, including monotherapy and combination approaches. Its continued enrollment will provide additional data on safety, pharmacokinetics, dosing and antitumor activity across KRAS-mutant cancers.
Alterome intends to further evaluate ALTA3263 in combination regimens and earlier treatment settings. In colorectal cancer, the company is continuing to investigate the combination with cetuximab, building on the preliminary response and disease-control findings. In pancreatic cancer, further development will focus on understanding the monotherapy activity and assessing the potential of combining ALTA3263 with standard-of-care treatments and targeted agents.
The pharmacokinetic results, particularly the approximately dose-proportional exposure observed between 100 mg and 400 mg twice daily and the exposure exceeding preclinical steady-state benchmarks at 400 mg twice daily, will also inform continued clinical development.
While the early findings are encouraging, larger and more mature clinical datasets will be necessary to establish the efficacy, safety, durability of responses and potential clinical role of ALTA3263. The ongoing study is expected to provide further information about its activity across different KRAS mutations and tumor types.
With its broad mutant KRAS inhibition strategy and preliminary clinical activity in colorectal and pancreatic cancers, ALTA3263 represents an investigational approach aimed at addressing persistent gaps in precision oncology. Alterome’s continued research will determine whether the therapy can provide a meaningful treatment option for patients whose cancers are driven by KRAS mutations beyond the currently targeted variants.
About Alterome Therapeutics, Inc.
Alterome Therapeutics, Inc. is a clinical-stage precision oncology company focused on discovering and developing alteration-specific therapeutics to address oncogenic drivers. The Company’s lead therapeutic candidate, ALTA3263, is an orally available, KRAS-selective, pan-mutant inhibitor targeting a broad range of oncogenic KRAS mutations in both the active (ON) and inactive (OFF) states while sparing HRAS and NRAS proteins whose inhibition may contribute to treatment-related toxicities.
ALTA3263 is currently being evaluated in a Phase 1/1b trial in advanced solid tumors with an initial focus on KRAS-mutant colorectal cancer and pancreatic ductal adenocarcinoma. Alterome is led by a team of precision oncology leaders with a history of discovering and developing novel oncology therapies.



